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Introduction
Conclusions
Human plasma cAMP pharmacokinetic profile
We developed a robust and selective method for quantifying cAMP in both urine and plasma.
 We also showed the utility in determining cAMP in biological systems. In SD rats, we were able to demonstrate the pharmacokinetic profile of PTH and cAMP after an oral administration of PTH(1-34).
The cyclic AMP response to an oral administration of PTH (1-34) at 1mg (PTH Tmax = 20-30min) was modest in the human and increased by up to 16 % 30min after ingestion.
 The diagnosis of PHP was confirmed in a patient as shown by the lack of change in the clearance ratio urine cAMP : creatinine after an sc administration of Forsteo which induced a 3-fold increase in
plasma PTH (1-34).
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Rat plasma cAMP pharmacokinetic profile
Graph showing the plasma cAMP (red) response to oral PTH (1-34) (blue) in Sprague-Dawley rats. 
In all 5 rats, plasma PTH and cAMP increased significantly and rapidly within 15 min of dosing,
reaching peak values between 15 and 30 min. PTH concentrations increased significantly by up to
6770-fold, although response to PTH is highly variable between animals. Mean plasma cAMP
typically tripled, from 36.5 ±3.7 nmol/L at baseline to a peak of 119.7 ± 26.3 nmol/L. Increase
was significant at 30 min and returned to normal 120 min after ingestion of 1000mg/kg of oral
PTH (1-34).
Increase  in plasma cAMP in human (n=8) in response to oral PTH (1-34) 
Eight human samples were analysed after oral administration of PTH(1-34) (1mg). Mean baseline
levels of PTH were 8pg/mL (range 8-10pg/mL). PTH Tmax was 20-30 min and and Cmax was 102 ±
24 pg/mL. The increase in plasma PTH was accompanied by a modest increase in plasma cAMP
(up to 16% by 30min relative to baseline), variable between individuals.
PTH was measured every 30 min, following a standard 20µg sc injection of teriparatide (Forsteo).
Plasma concentration of PTH increased from 28 to 83 pg/mL. Urinary cAMP concentrations were
measured by LCMS every 30 min, from 1hr before to 2hrs after injection and were standardized
against creatinine concentration. No significant changes in urine cAMP clearance was observed
following the injection of teriparatide.
cAMP in pseudohypoparathyroidism
Plasma PTH concentration and urine cAMP excretion after  subcutaneous 
injection of Forsteo in a patient with suspected PHP.
Chemical structure of 3’,5’- cAMP
 Develop and validate a high-performance liquid chromatography tandem mass spectrometry 
(LC-MS/MS) method for the quantification of cAMP in plasma and urine samples. 
 Investigate assay performance in pharmacokinetic studies investigating the response to an oral 
dose of PTH (1-34) in rats and humans. 
 Test urinary samples from a patient with suspected PHP.
Objectives
Methods
 LC-MS/MS method
- Purified cAMP (calibrators) was purchased from Sigma-
Aldrich and 13C5-cAMP internal standard from Toronto
Research Chemicals (Toronto, Canada). Analytes were
extracted from EDTA plasma using a weak anion exchange
solid phase extraction (MOD-SPE-CAMP-03-50,
Chromatography Direct Ltd., Runcorn, UK); urine was
injected without extraction. Chromatography was
performed in positive electrospray ionisation mode, using
a pentafluorophenyl column (MOD-LC-CAMP,
Chromatography Direct Ltd) with a 10 min 2% formic acid
water:acetonitrile gradient.
Transitions in the multiple reaction monitoring mode were
m/z 330/136 for cAMP and 335/136 for 13C5-cAMP. cAMP
was eluted within 3.0 min. Over concentrations ranging 4.6
(lower limit of quantification) to 293.5 nmol/L, the
calibration curve was linear (mean curve fits of >0.95, 5
repeats) and intra- and inter-assay precisions were <12%
and <8%, respectively. Spiked recovery was 98 ± 5%:
- PTH(1-34) was measure using the IDS-iSYS automated
immunoassay platform (IDS Ltd., Boldon, UK).
 Application:
- cAMP was analysed in 5 EDTA samples obtained from Sprague-Dawley (SD) rats. A single oral
dose of 1000 mg/kg PTH (1–34) (or placebo) was administered after an overnight fast. Blood
samples were obtained at baseline, prior to dosing and every 15 min for 2h and then hourly for
another 3h after dosing.
- A preliminary pharmacokinetic study was also performed in human (n=8) using a 1mg oral
administration of PTH(1-34).
- Urinary cAMP was also analysed in a patient with suspected PHP after PTH stimulation.
 Statistics
- Concentrations were compared using one-way ANOVA.
- SPSS for windows version 22.0.0.1 was used and results were considered statistically
significant for p<0.05. * p<0.05 vs 0 min and # p<0.05 vs 30 min.
Typical cAMP peak results 
from rat EDTA plasma
Typical cAMP standard curve
Parathyroid hormone (PTH) plays a key role in
calcium and phosphate homeostasis. Upon
binding to its receptor, it can signal via a second
messenger, the cyclic adenosine 3, 5’
monophosphate (cAMP). Plasma and urinary
cAMP concentrations are used as a diagnostic
marker for pseudohypoparathyroidism (PHP).
Patients may be asymptomatic or present with
skeletal phenotype (Albright's osteodystrophy)
and often short stature. Subcutaneous
calcification has been reported in the neonatal
period1. PHP is associated primarily with
resistance to the parathyroid hormone2. Patients
present with low serum calcium and high
phosphate, but the parathyroid hormone
concentration is high. The pathogenesis of PHP
has been linked to dysfunctional G Proteins (in
particular, Gs alpha subunit)3. In PHP patients,
cAMP fails to increase in response to PTH,
including the bioactive form PTH(1-34),
administration (Ellsworth-Howard Test).
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